TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graded exposure and activity
Description: 1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graded exposure and activity
Description: 1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner
Study: NCT02163720

Intervention type: DRUG
Intervention: Yondelis®-Caelyx®
Description: Observation of Yondelis®-Caelyx® administration
Study: NCT04972890

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: using 2 cc saline/NaCl 0,9% solution
Study: NCT01041586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTVA System
Description: Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
Study: NCT03268057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503 + avelumab
Description: Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
Study: NCT04193137

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral sodium loading test,Seated saline infusion test and Captopril challenge test
Description: Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral sodium loading test,Seated saline infusion test and Captopril challenge test
Description: Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge.
Study: NCT00794300

Intervention type: DEVICE
Intervention: second magnetic resonance imaging scan
Study: NCT01307254

Intervention type: PROCEDURE
Intervention: blood analysis
Description: A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)

Intervention type: PROCEDURE
Intervention: blood analysis
Description: A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
Study: NCT03794219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral naproxen
Description: 750 mg/day oral naproxen is administered for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naproxen
Description: 750 mg/day oral naproxen is administered for 10 days.
Study: NCT01054859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 200 mg avanafil tablet QD plus 0.5 g/kg alcohol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol
Description: 0.5 g/kg alcohol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avanafil
Description: 200 mg avanafil tablet QD
Study: NCT00773500

Intervention type: OTHER
Intervention: Electronic prescribing
Description: Implementation of a commercially available electronic prescribing system with clinical decision support

Intervention type: OTHER
Intervention: Electronic prescribing
Description: Implementation of a commercially available electronic prescribing system with clinical decision support
Study: NCT03560271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo (His-Pro) and zinc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo (His-Pro) and zinc
Study: NCT02345668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Protocol
Description: Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (Pharmacological Treatment)
Description: The Pharmacological Treatment provided by a psychiatrist in the mental health unit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (Psychological Treatment)
Description: The Psychological Treatment provided by a clinical psychologist in the mental health unit.
Study: NCT01023087

Intervention type: DRUG
Intervention: Polymyxin E (Colistin)
Description: Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.

Intervention type: DRUG
Intervention: Non-nephrotoxic antibiotics
Description: To be decided by the infectious disease consultant
Study: NCT02426775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carglumic Acid
Description: Carglumic Acid 50 mg/kg/day (twice daily)
Study: NCT00381784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed materials
Description: Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors.
Study: NCT00381784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer advocates
Description: Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers.
Study: NCT01943266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein intake
Description: on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
Study: NCT03560271

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00800319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-0313
Description: Oral solution given in 5, 15, 25, 50, and 75 mg single doses
Study: NCT01646736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F
Description: Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
Study: NCT00800319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-0313
Description: Oral solution given in 5, 15, 25, 50, and 75 mg single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-0313
Description: Oral solution given in 5, 15, 25, 50, and 75 mg single doses
Study: NCT01646736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1.0 intravenous every month.
Study: NCT04519125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
Description: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
Description: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
Study: NCT02518828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High SpO2
Description: SpO2 range ≥96%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low SpO2
Description: SpO2 range 90-92%
Study: NCT01646736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GC
Description: Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC
Description: Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
Study: NCT02506972

Intervention type: OTHER
Group type: OTHER
Intervention: Classic Quaker Quick Oats
Description: Various doses of oats without or with sugar

Intervention type: OTHER
Group type: OTHER
Intervention: Classic Quaker Quick Oats
Description: Various doses of oats without or with sugar

Intervention type: OTHER
Group type: OTHER
Intervention: Classic Quaker Quick Oats
Description: Various doses of oats without or with sugar

Intervention type: OTHER
Group type: OTHER
Intervention: Classic Quaker Quick Oats
Description: Various doses of oats without or with sugar
Study: NCT02506972

Intervention type: OTHER
Group type: OTHER
Intervention: Cream of Rice Cereal
Description: Various doses of cereal without sugar

Intervention type: OTHER
Group type: OTHER
Intervention: Cream of Rice Cereal
Description: Various doses of cereal without sugar
Study: NCT04056676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block under ultrasound guidance
Description: Ultrasound-guided thoracic paravertebral blocks in T2, T4 level

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative modified PEC block
Description: Pectoral nerve block by surgeon under direct vision after total mastectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative modified PEC block
Description: Pectoral nerve block by surgeon under direct vision after total mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA with ETT
Description: General anesthesia with endotracheal intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GA with ETT
Description: General anesthesia with endotracheal intubation
Study: NCT02633644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmony System
Description: Percutaneous neuromodulation of the aortic wall
Study: NCT03339960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic measurement
Description: Ergonomic measurement of the surgeon and assistant
Study: NCT00842712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
Study: NCT03776760

Intervention type: DEVICE
Intervention: Fingerstick GeneXpert HCV RNA quantitative assay
Description: All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly

Intervention type: DRUG
Intervention: sofosbuvir/velpatesvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia

Intervention type: DRUG
Intervention: sofosbuvir/velpatesvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia

Intervention type: DRUG
Intervention: glecaprevir/pibrentasvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia

Intervention type: DRUG
Intervention: glecaprevir/pibrentasvir
Description: Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
Study: NCT04009291

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TransCon PTH
Description: TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TransCon PTH
Description: Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
Study: NCT01420757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Tension-free open or laparoscopic incisional hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Tension-free open or laparoscopic incisional hernia repair
Study: NCT02906137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral blood and intestinal biopsies will be collected
Description: Blood draw and intestinal biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood and intestinal biopsies will be collected
Description: Blood draw and intestinal biopsies
Study: NCT03735381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer watch 'Xiomi mi band2'
Description: 1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer watch 'Xiomi mi band2'
Description: 1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group).
Study: NCT03673618

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Corn Fiber
Description: Fiber or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Corn Fiber
Description: Fiber or placebo
Study: NCT01708278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar chew
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar chew
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar chew
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)